Spinocerebellar Ataxia – Epidemiology – Mature Markets Data
Clarivate Epidemiology’s coverage of spinocerebellar ataxia (SCA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of SCA for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s spinocerebellar ataxia forecast will answer the following questions:
- Of all people with SCA, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- Among all people with subtypes of SCA, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four SCA patient populations, as follows:
- Diagnosed prevalent cases of SCA.
- Diagnosed prevalent cases of type 1 SCA.
- Diagnosed prevalent cases of type 2 SCA.
- Diagnosed prevalent cases of type 3 SCA.
Note: Coverage may vary by country.
